Psychosocial impact of breast ovarian ( ) cancer-predictive genetic testing in a UK multi-centre clinical cohort

This multi-centre UK study assesses the impact of predictive testing for breast and ovarian cancer predisposition genes (BRCA1/2) in the clinical context. In the year following predictive testing, 261 adults (59 male) from nine UK genetics centres participated; 91 gene mutation carriers and 170 nonc...

Full description

Saved in:
Bibliographic Details
Published in:British journal of cancer 2004-11, Vol.91 (10), p.1787-1794
Main Authors: Watson, M, Foster, C, Eeles, R, Eccles, D, Ashley, S, Davidson, R, Mackay, J, Morrison, P J, Hopwood, P, Evans, D G R
Format: Article
Language:English
Subjects:
Adult
Age Factors
Anxiety
Breast Neoplasms - genetics
Breast Neoplasms - psychology
Clinical
Cohort Studies
Female
Genes, BRCA1
Genes, BRCA2
Genetic Predisposition to Disease
Genetic Testing - psychology
Heterozygote
Humans
Insurance Selection Bias
Male
Middle Aged
Mutation
Ovarian Neoplasms - genetics
Ovarian Neoplasms - psychology
Risk Management
Sex Factors
Surveys and Questionnaires
United Kingdom
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This multi-centre UK study assesses the impact of predictive testing for breast and ovarian cancer predisposition genes (BRCA1/2) in the clinical context. In the year following predictive testing, 261 adults (59 male) from nine UK genetics centres participated; 91 gene mutation carriers and 170 noncarriers. Self-report questionnaires were completed at baseline (pre-genetic testing) and 1, 4 and 12 months following the genetic test result. Men were assessed for general mental health (by general health questionnaire (GHQ)) and women for general mental health, cancer-related worry, intrusive and avoidant thoughts, perception of risk and risk management behaviour. Main comparisons were between female carriers and noncarriers on all measures and men and women for general mental health. Female noncarriers benefited psychologically, with significant reductions in cancer-related worry following testing (P
ISSN:0007-0920
1532-1827
DOI:10.1038/sj.bjc.6602207